文献速递神经肌肉病

肌萎缩侧索硬化症前驱期轻度运动障碍的研究标准提案

Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis.
PubMed 文献 · Neurology · 2025-07-28

本研究基于Pre-fALS纵向队列提出轻度运动障碍(MMI)的操作性研究标准,并在遗传多样性人群中描述其频率及与ALS表型转化时间的关联。结果显示,基线存在MMI的突变携带者表型转化风险显著升高(HR 5.1,95%CI 2.2-12.2,p<0.0001),提示MMI可作为识别ALS前驱期高危携带者的可识别综合征。

要点

  • MMI定义为满足7条标准中至少1条,反映无对应无力的上/下运动神经元征象。
  • 31例表型转化者中17例(55%)在临床发病前至少一次访视符合MMI。
  • 基线有MMI的突变携带者表型转化风险显著高于无MMI者(HR 5.1)。

核心结论

  • MMI是一种可识别的综合征,虽非特异,但可识别表型转化风险升高的无症状携带者。

研究设计与样本

  • Pre-fALS研究为2007年启动的纵向自然病史与生物标志物研究,纳入任何ALS相关致病性变异的未受影响携带者。
  • 研究队列包括49名对照(平均年龄38.9岁,61%女性)、153名无症状携带者(平均年龄43.1岁,61%女性)和31例ALS表型转化者(平均年龄54.4岁,58%女性)。
  • 基于Pre-fALS研究中表型转化者病史的临床回顾制定MMI研究标准,并系统应用于其余队列。

主要发现

  • 31例表型转化者中17例(55%)在临床发病前至少一次访视符合MMI。
  • 153名尚未表型转化的无症状携带者中66例(43%)符合MMI,49名对照中7例(14%)符合MMI。
  • 基线有MMI与无MMI的突变携带者,表型转化时间第25百分位(95%CI)分别为3.7(1.6-4.7)年和14.1(8.9-∞)年。
  • Cox模型显示MMI与表型转化的风险比为5.1(95%CI 2.2-12.2,p<0.0001)。
  • 年龄每增加10年,表型转化风险率为1.7倍,且随基因型变化。

关键数值与推荐

  • 提出7条MMI标准,每条反映1个或多个(共4个)拓扑区域中无对应无力的不同上/下运动神经元征象模式。
  • MMI定义为满足至少1条上述标准。

临床怎么用

  • MMI可作为识别ALS前驱期高危携带者的临床综合征,结合新兴病理生物标志物可能有助于区分前驱期与非前驱期个体。
  • MMI的刻画与研究(包括在其他研究中的重复验证)可能促进早期治疗干预和ALS预防工作。

局限性

  • MMI为非特异性综合征,对照中亦有14%符合MMI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The presymptomatic stage of amyotrophic lateral sclerosis (ALS) is typically assumed to be clinically silent. Our previous work, however, has revealed evidence of a prodromal stage, termed mild motor impairment (MMI). In this study, we propose operational criteria for MMI, describe its frequency in a genetically diverse cohort, and examine the association between MMI and time to ALS phenoconversion. METHODS: Pre-Symptomatic Familial ALS (Pre-fALS) study, initiated in 2007, is a longitudinal natural history and biomarker study of unaffected carriers of any ALS-associated pathogenic variant. Proposed research criteria for MMI were developed based on clinical review of case histories of ALS phenoconverters in the Pre-fALS study. These criteria were then systematically applied to the remaining Pre-fALS cohort. Among phenoconverters and presymptomatic carriers, cumulative probabilities of phenoconversion were estimated for those with and without MMI at baseline. Cox proportional hazard models evaluated associations between risk factors (MMI, age, genotype) and time from baseline to ALS phenoconversion. RESULTS: The study cohort includes 49 controls (mean age 38.9, 61% female), 153 presymptomatic carriers (mean age 43.1, 61% female), and 31 ALS phenoconverters (mean age 54.4, 58% female). Seven criteria for MMI are proposed, each reflecting a different pattern of upper/lower motor neuron signs, without corresponding weakness, in 1 or more of 4 topographic regions. MMI, defined as meeting ≥1 of these criteria, was observed at 1 or more study visits in 17 of 31 phenoconverters (55%) before clinically manifest ALS, 66 of 153 presymptomatic carriers (43%) who had not yet phenoconverted, and 7 of 49 controls (14%). Among all mutation carriers, the 25th percentile (95% CI) of time to phenoconversion was, respectively, 3.7 (1.6-4.7) and 14.1 (8.9-∞) years for those with and without MMI at baseline, with a hazard ratio of 5.1 (95% CI 2.2-12.2, p < 0.0001). Moreover, the hazard rate of phenoconversion was 1.7 times higher for every 10-year increase in age and varied by genotype. DISCUSSION: MMI is a recognizable syndrome. Although nonspecific, it identifies presymptomatic carriers at elevated risk of ALS phenoconversion. Combining MMI with emerging biomarkers of underlying pathology may help differentiate those who are prodromal from those who are not prodromal for ALS. Characterization and study of MMI, including replication in other studies, may empower early therapeutic intervention and ALS prevention efforts.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Benatar M, Cai X, McDermott MP, et al. Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis. Neurology. 2025. PMID: 40720712. doi:10.1212/WNL.0000000000213917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。